Across glioma models—C6, U-87MG, and GL261—211At-labeled phenylalanine analogs produced dose-dependent tumor suppression at 0.1–1 MBq/mouse, with BCH competitively reducing cellular uptake, consistent with system-L/LAT1 transport [165]. The gene discussed is SLC7A5; the disease is neoplasm.